Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre
Sukriti Gupta,1 Priyanka Singh,2 Mrityunjay Singh,1 Mayuresh Naik,3 Kartikeya Srivastava1 1Department of Ophthalmology, V.M.M.C & Safdarjung Hospital, New Delhi, 110029, India; 2Department of Ophthalmology, ESI Medical College and Hospital, Faridabad, Haryana, 121012, India; 3Department of Ophth...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f314816fdf0345bfa5a908652a5188be |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f314816fdf0345bfa5a908652a5188be |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f314816fdf0345bfa5a908652a5188be2021-12-02T16:12:38ZIs Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre1177-5483https://doaj.org/article/f314816fdf0345bfa5a908652a5188be2021-07-01T00:00:00Zhttps://www.dovepress.com/is-interferon--2b-1-millioniuml-truly-better-than-tacrolimus-003-for-s-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Sukriti Gupta,1 Priyanka Singh,2 Mrityunjay Singh,1 Mayuresh Naik,3 Kartikeya Srivastava1 1Department of Ophthalmology, V.M.M.C & Safdarjung Hospital, New Delhi, 110029, India; 2Department of Ophthalmology, ESI Medical College and Hospital, Faridabad, Haryana, 121012, India; 3Department of Ophthalmology, H.I.M.S.R & H.A.H. Centenary Hospital, New Delhi, 110062, IndiaCorrespondence: Mayuresh NaikDepartment of Ophthalmology, H.I.M.S.R & H.A.H. Centenary Hospital, Room no. 3 of Eye OPD, 1st Floor of OPD Building, Near GK-2, Alaknanda, New Delhi, 110062, IndiaTel +91-8287344576Email mayureshpnaik@gmail.comPurpose: To compare the efficacy of eye-drop interferon (IFN) α-2b 1 millionIU/mL with eye-ointment tacrolimus 0.03% in refractory vernal keratoconjunctivitis (VKC).Materials and Methods: Fifty patients with VKC refractory to conventional treatment with topical corticosteroids and antihistamines after 4 weeks of regular use were selected retrospectively. Patients were divided into two groups depending on whether they received eye-ointment tacrolimus 0.03% three times a day or eye-drop IFN alpha-2b 1 millionIU/mL three times a day and were followed up for 24 months. The main outcome measures were total subjective symptom score (TSSS) and total objective ocular score (TOSS).Results: Mean baseline TSSS was 7.24± 1.98 in Group A (tacrolimus group) and 7.84± 1.82 in Group B (IFN group), and it reduced to 1.12± 0.83 in Group A and 0.62± 0.41 in Group B at 6 months, which was statistically significant compared to the baseline score (p< 0.05) as well as between the two groups. Mean baseline TOSS was 6.72± 2.07 in Group A and 6.56± 2.04 in Group B, and it improved to 1 month onwards to 1.52± 0.87 in Group A and 1.0± 0.71 in Group B at 6 months, which was statistically significant compared to the baseline score (p< 0.05) as well as between the two groups. Side effects like stinging and burning sensations were seen in the tacrolimus group only.Conclusion: Our study suggests that while both eye-drop IFN α-2b 1 millionIU/mL and eye-ointment tacrolimus eye ointment 0.03% are both safe and effective steroid-sparing agents in steroid-resistant VKC. IFN α-2b results in greater improvement in subjective symptoms and objective signs, has fewer side effects in long term and is better tolerated as compared to tacrolimus.Keywords: refractory vernal keratoconjunctivitis, tacrolimus, interferon α-2b, VKCGupta SSingh PSingh MNaik MSrivastava KDove Medical Pressarticlerefractory vernal keratoconjunctivitis; tacrolimusinterferon α-2b; vkc .OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 2993-2999 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
refractory vernal keratoconjunctivitis; tacrolimus interferon α-2b; vkc . Ophthalmology RE1-994 |
| spellingShingle |
refractory vernal keratoconjunctivitis; tacrolimus interferon α-2b; vkc . Ophthalmology RE1-994 Gupta S Singh P Singh M Naik M Srivastava K Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
| description |
Sukriti Gupta,1 Priyanka Singh,2 Mrityunjay Singh,1 Mayuresh Naik,3 Kartikeya Srivastava1 1Department of Ophthalmology, V.M.M.C & Safdarjung Hospital, New Delhi, 110029, India; 2Department of Ophthalmology, ESI Medical College and Hospital, Faridabad, Haryana, 121012, India; 3Department of Ophthalmology, H.I.M.S.R & H.A.H. Centenary Hospital, New Delhi, 110062, IndiaCorrespondence: Mayuresh NaikDepartment of Ophthalmology, H.I.M.S.R & H.A.H. Centenary Hospital, Room no. 3 of Eye OPD, 1st Floor of OPD Building, Near GK-2, Alaknanda, New Delhi, 110062, IndiaTel +91-8287344576Email mayureshpnaik@gmail.comPurpose: To compare the efficacy of eye-drop interferon (IFN) α-2b 1 millionIU/mL with eye-ointment tacrolimus 0.03% in refractory vernal keratoconjunctivitis (VKC).Materials and Methods: Fifty patients with VKC refractory to conventional treatment with topical corticosteroids and antihistamines after 4 weeks of regular use were selected retrospectively. Patients were divided into two groups depending on whether they received eye-ointment tacrolimus 0.03% three times a day or eye-drop IFN alpha-2b 1 millionIU/mL three times a day and were followed up for 24 months. The main outcome measures were total subjective symptom score (TSSS) and total objective ocular score (TOSS).Results: Mean baseline TSSS was 7.24± 1.98 in Group A (tacrolimus group) and 7.84± 1.82 in Group B (IFN group), and it reduced to 1.12± 0.83 in Group A and 0.62± 0.41 in Group B at 6 months, which was statistically significant compared to the baseline score (p< 0.05) as well as between the two groups. Mean baseline TOSS was 6.72± 2.07 in Group A and 6.56± 2.04 in Group B, and it improved to 1 month onwards to 1.52± 0.87 in Group A and 1.0± 0.71 in Group B at 6 months, which was statistically significant compared to the baseline score (p< 0.05) as well as between the two groups. Side effects like stinging and burning sensations were seen in the tacrolimus group only.Conclusion: Our study suggests that while both eye-drop IFN α-2b 1 millionIU/mL and eye-ointment tacrolimus eye ointment 0.03% are both safe and effective steroid-sparing agents in steroid-resistant VKC. IFN α-2b results in greater improvement in subjective symptoms and objective signs, has fewer side effects in long term and is better tolerated as compared to tacrolimus.Keywords: refractory vernal keratoconjunctivitis, tacrolimus, interferon α-2b, VKC |
| format |
article |
| author |
Gupta S Singh P Singh M Naik M Srivastava K |
| author_facet |
Gupta S Singh P Singh M Naik M Srivastava K |
| author_sort |
Gupta S |
| title |
Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
| title_short |
Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
| title_full |
Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
| title_fullStr |
Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
| title_full_unstemmed |
Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
| title_sort |
is interferon α-2b 1 millioniu/ml truly better than tacrolimus 0.03% for steroid-resistant vkc ?: our 2-year experience at a tertiary health-care centre |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/f314816fdf0345bfa5a908652a5188be |
| work_keys_str_mv |
AT guptas isinterferonalpha2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT singhp isinterferonalpha2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT singhm isinterferonalpha2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT naikm isinterferonalpha2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT srivastavak isinterferonalpha2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre |
| _version_ |
1718384384638189568 |